Join
Live feed
·
PRReleasevia Quantisnow
Summit Therapeutics Inc. logo

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

ByQuantisnow·Wall Street's wire, on your screen.
SMMT· Summit Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SMMT (Summit Therapeutics Inc.) and more on Quantisnow.